HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RSLV-132

fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1

Also Known As:

RSLV132

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barone, Francesca: 1 article (01/2021)
2.	Burge, Daniel: 1 article (01/2021)
3.	Casement, John: 1 article (01/2021)
4.	Davies, Kristen: 1 article (01/2021)
5.	Fisher, Benjamin A: 1 article (01/2021)
6.	Gallagher, Peter: 1 article (01/2021)
7.	Jobling, Kerry: 1 article (01/2021)
8.	Ng, Wan-Fai: 1 article (01/2021)
9.	Posada, James: 1 article (01/2021)
10.	Tarn, Jessica: 1 article (01/2021)

Related Diseases

1.	Fatigue 01/01/2021 - "Administration of RSLV-132 improved severe fatigue, as determined by 4 independent patient-reported measures of fatigue, in patients with primary SS." 01/01/2021 - "Eight patients received placebo and 20 patients received RSLV-132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST). "
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/01/2017 - "Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study."
3.	Rheumatic Diseases (Rheumatism) 01/01/2021 - "Eight patients received placebo and 20 patients received RSLV-132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST). "
4.	Chronic Disease (Chronic Diseases) 01/01/2021 - "Eight patients received placebo and 20 patients received RSLV-132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST). "

Related Drugs and Biologics

1.	Ribonucleases (Ribonuclease)
2.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics